 |
|
|
= Add Release to Briefcase |
| All Releases |
 |
ZIOPHARM Receives Notices of Allowance for Two U.S. Patent Applications Covering Darinaparsin
May 13, 2008
|
9.0 KB
|
| |
NEW YORK, May 13, 2008 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today that it has received Notices of Allowance from the U.S. Patent and Trademark Office for patent applications numbered 11/252,966 and 11/349,043, covering claims for various organic arsenic compounds, including purified crystalline darinaparsin, glycolic ...
|
|
 |
ZIOPHARM Oncology Reports First Quarter Results
May 12, 2008
|
9.7 KB
|
| |
NEW YORK, May 12, 2008 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) today reported financial results for the three months ended March 31, 2008.
The Company reported a net loss for the first quarter of 2008 of $8.6 million, or $(0.41) per share, compared with a net loss for the first quarter of 2007 of $5.0 million, or $(0.29) per s...
|
|
 |
ZIOPHARM Oncology to Present at Rodman and Renshaw 5th Annual Global Healthcare Conference
May 12, 2008
|
7.8 KB
|
| |
NEW YORK, May 12, 2008 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today that Dr. Jonathan Lewis, Chief Executive Officer, will present at the Rodman and Renshaw 5th Annual Global Healthcare Conference on Monday, May 19, 2008 at 9:20 am GMT +1 (3:20 AM ET) in the Atlantique Salon - Meridional at Le Meridien Beach Plaza Hotel...
|
|
 |
ZIOPHARM Receives FDA Orphan Drug Designation for Palifosfamide (ZIO-201) in the Treatment of Soft Tissue Sarcoma
May 9, 2008
|
9.9 KB
|
| |
NEW YORK, May 09, 2008 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), announced today that the United States Food & Drug Administration (FDA) has granted Orphan Drug Designation to palifosfamide in the treatment of Soft Tissue Sarcoma (STS). The United States Orphan Drug Act of 1983 was created to provide incentives for companies to dev...
|
|
 |
ZIOPHARM Announces 2008 Annual Meeting of Stockholders
Apr 17, 2008
|
8.1 KB
|
| |
NEW YORK, Apr 17, 2008 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today it will hold its Annual Meeting of Stockholders on Wednesday, April 23, 2008 at 9:00 a.m. ET in the Saybrook Room at the Yale Club. Stockholders of record at the close of business on March 19, 2008 are entitled to vote at the Annual Meeting. Dr. Jonatha...
|
|
 |
ZIOPHARM Presents Positive Data from Phase II Study of Darinaparsin in Advanced Hematological Malignancies at AACR 2008 Annual Meeting
Apr 16, 2008
|
9.9 KB
|
| |
SAN DIEGO, Apr 16, 2008 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) announced today that it presented positive data from a phase II study of darinaparsin, the Company's novel organic arsenic compound, in advanced hematological malignancies at the American Association for Cancer Research (AACR) Annual Meeting, April 12-16, 2008 in San D...
|
|
 |
ZIOPHARM to Present at 8th Annual Fortis Bank Biotechnology Conference in London
Mar 27, 2008
|
7.8 KB
|
| |
NEW YORK, Mar 27, 2008 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) announced today Dr. Jonathan Lewis, Chief Executive Officer, will present at the 8th Annual Fortis Bank Biotechnology Conference on Thursday, April 3, 2008 at 2:00 p.m. GMT (9:00 a.m. ET) at the Four Seasons Hotel Park Lane in London, United Kingdom.
Dr. Lewis will ...
|
|
 |
ZIOPHARM Presents Promising Early Data from Phase Ib Study of Indibulin at 6th International Symposium on Targeted Anticancer Therapies
Mar 20, 2008
|
9.9 KB
|
| |
BETHESDA, Md., Mar 20, 2008 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) announced today that it presented promising early data from a Phase Ib study of indibulin, the Company's novel, orally administered, synthetic tubulin targeted agent, at the 6th International Symposium on Targeted Anticancer Therapies held in Bethesda, Maryland, Ma...
|
|
 |
ZIOPHARM Appoints Steven Bloom as Vice President, Business Development and Barry Jones, Ph.D., as Senior Vice President, Preclinical Operations
Mar 3, 2008
|
9.3 KB
|
| |
NEW YORK, Mar 03, 2008 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today that it has appointed Steven Bloom as Vice President, Business Development and Barry Jones, Ph.D., as Senior Vice President, Preclinical Operations. Both new executives will operate out of ZIOPHARM's Boston office and report to President and Chief Opera...
|
|
 |
ZIOPHARM Reports Fourth Quarter and Full Year 2007 Financial Results
Feb 22, 2008
|
11.7 KB
|
| |
NEW YORK, Feb 22, 2008 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs, announced today its financial results for the fourth quarter and full year 2007 and the fili...
|
|
 |
ZIOPHARM Oncology to Present at Roth 20th Annual OC Growth Stock Conference
Feb 5, 2008
|
7.7 KB
|
| |
NEW YORK, Feb 05, 2008 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today that Dr. Jonathan Lewis, Chief Executive Officer, will present at the Roth 20th Annual OC Growth Stock Conference on Tuesday, February 19, 2008 at 10:30 am PT (1:30 PM ET) in the Promenade Room at the Ritz Carlton Laguna Niguel in Laguna Niguel, CA. Dr....
|
|
 |
ZIOPHARM Commences Treatment of First Patients in Two Separate Phase I/II Combination Studies of Both Indibulin and Palifosfamide
Feb 4, 2008
|
9.2 KB
|
| |
NEW YORK, Feb 04, 2008 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), announced today that dosing of the first patient took place in two separate new studies, including:
-- A Phase I/II combination study evaluating oral indibulin (ZIO-301) combined with oral Tarceva® (erlotinib) in the t...
|
|
 |
ZIOPHARM to Present at the BMO Capital Markets Focus on Healthcare Conference
Dec 3, 2007
|
7.7 KB
|
| |
NEW YORK, Dec 03, 2007 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today that Dr. Jonathan Lewis, Chief Executive Officer, will present at the BMO Capital Markets Focus on Healthcare Conference on Tuesday December 4, 2007 at 2:00 p.m. ET at the Millennium Broadway Hotel in New York, NY. Dr. Lewis will provide an overview of ...
|
|
 |
ZIOPHARM to Host Analyst & Institutional Investor Meeting
Nov 15, 2007
|
9.3 KB
|
| |
NEW YORK, Nov 15, 2007 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today that the Company will host an analyst and institutional investor meeting on Thursday, November 29, 2007 from 7:30 A.M. to 10:00 A.M. Eastern Time at The Yale Club of New York City (50 Vanderbilt Avenue between E. 44th & E. 45th Streets). Presentations a...
|
|
 |
ZIOPHARM Presents Positive Phase II Data for ZIO-201 in Soft Tissue and Bone Sarcomas at Connective Tissue Oncology Society (CTOS) Annual Meeting
Nov 5, 2007
|
14.7 KB
|
| |
NEW YORK, Nov 05, 2007 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today the presentation of positive data from an ongoing Phase II study of ZIO-201 used in soft tissue and bone sarcomas at the Connective Tissue Oncology Society (CTOS) Annual Meeting which was held in Seattle, Washington from November 1-3, 2007.
The Phas...
|
|
 |
ZIOPHARM Oncology Reports Third Quarter Results
Nov 2, 2007
|
14.2 KB
|
| |
NEW YORK, Nov 02, 2007 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs, today reported financial results for the three and nine months ended September 30, 2007.
...
|
|
 |
ZIOPHARM Oncology to Present at MASS Opps Partnering Forum
Nov 1, 2007
|
11.7 KB
|
| |
NEW YORK, Nov 01, 2007 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today that Dick Bagley, President and COO will present at the MASS Opps Partnering Forum on Thursday, November 8, 2007 at 10:55 am ET at the Hilton Boston Logan Airport in Boston, MA. Mr. Bagley will provide an overview of the Company and an update on its cli...
|
|
 |
ZIOPHARM to Present at Rodman & Renshaw 9th Annual Healthcare Conference
Oct 29, 2007
|
12.1 KB
|
| |
NEW YORK, Oct 29, 2007 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today that Dr. Jonathan Lewis, Chief Executive Officer, will present at the Rodman & Renshaw 9th Annual Healthcare Conference on Monday, November 5, 2007 at 2:40 p.m. ET at the Palace Hotel in New York, NY. Dr. Lewis will provide an overview of the Company an...
|
|
 |
Clinical and Preclinical Data for Oral Indibulin (ZIO-301) Presented at AACR/NCI/EORTC Conference
Oct 25, 2007
|
15.1 KB
|
| |
SAN FRANCISCO, Oct 25, 2007 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today the presentation of two posters reporting clinical and pre-clinical data for the oral administration of indibulin (ZIO-301) at the Molecular Targets and Cancer Therapeutics Conference, an international conference hosted by the American Association ...
|
|
 |
ZIOPHARM to Present at the BIO Investor Forum
Oct 3, 2007
|
12.1 KB
|
| |
NEW YORK, Oct 03, 2007 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today that Dr. Barbara Wallner, Senior Vice President, Technical Operations and Chief Technology Officer, will present at the BIO Investor Forum on Wednesday, October 10, 2007 at 10:45 a.m. PT (1:45 ET) at the Palace Hotel in San Francisco, CA. Dr. Wallner wi...
|
|
|
|  |
Recent Releases
May 13, 2008
ZIOPHARM Receives Notices of Allowance for Two U.S. Patent Applications Covering Darinaparsin
May 12, 2008
ZIOPHARM Oncology Reports First Quarter Results
May 12, 2008
ZIOPHARM Oncology to Present at Rodman and Renshaw 5th Annual Global Healthcare Conference
more »
|